[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646328":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":58,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with hemophilia A",null,"The study plans to recruit participants with severe (FVIII \\\u003C1%) and moderate (FVIII 1-4%) HA.",[13,14],"Drug: Half-life factor VIII based replacement therapy","Drug: Non-FVIII based replacement therapy",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Half-life factor VIII based replacement therapy","Children with moderate or severe hemophilia A being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) as part of their hemophilia treatment to prevent spontaneous joint bleeds.",[9],[22],"Altuviiio",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Non-FVIII based replacement therapy","Children with moderate or severe hemophilia A being treated with non-FVIII based replacement therapy (such as Hemlibra) as part of their hemophilia treatment to prevent spontaneous joint bleeds.",[9],[28],"Hemlibra",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Jessica Garcia, MD","CONTACT","214-456-7000","Jessica.Garcia@UTSouthwestern.edu",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The University of Texas Southwestern Medical Center","Dallas","Texas","75235","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.80667,32.78306,{"lat":47,"lon":46},[50,51,53,56],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},{"name":31,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":10,"phoneExt":10,"email":10},"Guy Young, MD","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":10,"phoneExt":10,"email":10},"Ayesha Zia, MD",{"type":52,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jessica Garcia","Assistant Professor of Pediatrics",[62],{"name":63,"class":64},"Sanofi","INDUSTRY","100646328","tg-insight-with-joint-pocus-hemostatic-potential-in-patients-with-severe-hemophilia-a-on-novel-replacement-and-substitution-fviii-therapies-100646328",false,"NCT07692217","TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies","Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies (TG-INSIGHT With Joint POCUS)","Inclusion Criteria:\n\n* Participants with moderate or severe HA who are on prophylaxis with either weekly, biweekly, or every 4-weeks emicizumab or weekly efanesoctocog alfa for at least 2 months.\n* \\>6 months of age\n\nExclusion Criteria:\n\n* Participants with active FVIII inhibitor (\\>0.5 BU\u002FmL)\n* Presence of an additional bleeding disorder other than hemophilia A","ALL","6 Months",{"count":75,"type":76},60,"ESTIMATED","OBSERVATIONAL","This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.",[80,81],"Hemophilia A","Factor VIII (FVIII)","NOT_YET_RECRUITING","2026-07-02",{"date":85,"type":86},"2026-07-09","ACTUAL",{"date":88,"type":76},"2026-07",{"date":90,"type":76},"2033-05",{"name":5,"class":6},1]